Verified Researcher Certificate
Active ResearchRank profile with at least one indexed scholarly output
RESEARCHER PUBLIC RESEARCH PROFILE● Verified public profile
RRK-A-5054-0669-91
Rajita J. Vatapalli
Works73
Citations1,613
h-index15
i10-index16
2-year citedness12.00
Mean FWCI*4.78
Top 1%*2
Top 10%*11
ResearchRank IDRRK-A-5054-0669-91
Observed nameRajita J. Vatapalli
ORCIDNot linked
Current / last-known institutionAstraZeneca (United States)
Research topicsProstate Cancer Treatment and Research · Epigenetics and DNA Methylation · Chromatin Remodeling and Cancer · Lung Cancer Treatments and Mutations · Protein Degradation and Inhibitors
Name variantsR. Vatapalli, R.J. Vatapalli, Rajita J Vatapalli, Rajita J. Vatapalli, Rajita Vatapalli, Vatapalli, Rajita
FULL PROFILE ANALYSIS
Rajita J. Vatapalli - detailed research intelligence
Identity, scholarly output, impact indicators, affiliations, topics and publication evidence for this ResearchRank record.
Profile typeResearcher
Works73
Citations1,613
h-index15
i10-index16
Current / last-known affiliationAstraZeneca (United States)
ORCIDNot linked
Name variantsR. Vatapalli, R.J. Vatapalli, Rajita J Vatapalli, Rajita J. Vatapalli, Rajita Vatapalli, Vatapalli, Rajita
Primary research topics
Prostate Cancer Treatment and ResearchEpigenetics and DNA MethylationChromatin Remodeling and CancerLung Cancer Treatments and MutationsProtein Degradation and Inhibitors
Prostate Cancer Treatment and ResearchEpigenetics and DNA MethylationChromatin Remodeling and CancerLung Cancer Treatments and MutationsProtein Degradation and Inhibitors
RESEARCH ACHIEVEMENT SNAPSHOT
Evidence-backed profile highlights
This public profile presents scholarly evidence and recognition indicators without displaying certificate prices or checkout controls.
Research Output Certificate
At least 10 indexed scholarly works
Citation Impact Certificate
At least 100 indexed citations
h-index Achievement Certificate
h-index of 10 or higher
Sustained Research Output Certificate
At least 50 indexed scholarly outputs
Public profile: Research metrics and recognition evidence are shown for professional sharing. Commercial pricing and registration controls are intentionally omitted.
Extended publication analytics and related-profile intelligence are loading in the background. The full profile details below remain available even if the live analytics service is temporarily slow.
TOP-CITED OUTPUT
Full profile view · up to 25 leading worksResearch works
Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance ImmunotherapyArticle · 2019 · 466 citations · Open access · FWCI 18.2575 · Full text ↗
Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancersArticle · 2014 · 431 citations · Open access · FWCI 16.6627 · Full text ↗
Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancerArticle · 2020 · 108 citations · Open access · FWCI 9.1485 · Full text ↗
Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cellsArticle · 2017 · 101 citations · Open access · FWCI 4.9414 · Full text ↗
Frequent Inactivation of Cysteine Dioxygenase Type 1 Contributes to Survival of Breast Cancer Cells and Resistance to AnthracyclinesArticle · 2013 · 87 citations · Open access · FWCI 3.5805 · Full text ↗
Activated ALK Cooperates with N-Myc via Wnt/β-Catenin Signaling to Induce Neuroendocrine Prostate CancerArticle · 2021 · 70 citations · Open access · FWCI 10.0267 · Full text ↗
EPHB4 inhibition activates ER stress to promote immunogenic cell death of prostate cancer cellsArticle · 2019 · 54 citations · Open access · FWCI 4.9593 · Full text ↗
A Genome-Wide CRISPR Activation Screen Identifies PRRX2 as a Regulator of Enzalutamide Resistance in Prostate CancerArticle · 2022 · 46 citations · Open access · FWCI 6.4472 · Full text ↗
Outlier Analysis Defines Zinc Finger Gene Family DNA Methylation in Tumors and Saliva of Head and Neck Cancer PatientsArticle · 2015 · 40 citations · Open access · FWCI 2.6039 · Full text ↗
The Role of Castration-Resistant Bmi1+Sox2+ Cells in Driving Recurrence in Prostate CancerArticle · 2018 · 37 citations · Open access · FWCI 3.1996 · Full text ↗
Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cellsArticle · 2017 · 36 citations · Open access · FWCI 1.8979 · Full text ↗
Dose-Dependent Activation of Putative Oncogene SBSN by BORISArticle · 2012 · 35 citations · Open access · FWCI 1.1562 · Full text ↗
Cancer epigenetic therapy: recent advances, challenges, and emerging opportunitiesReview · 2024 · 24 citations · Open access · FWCI 0.9765 · Full text ↗
Integrative computational analysis of transcriptional and epigenetic alterations implicatesDTX1as a putative tumor suppressor gene in HNSCCArticle · 2017 · 18 citations · Open access · FWCI 3.4197 · Full text ↗
Inflammatory bowel disease induces inflammatory and pre-neoplastic changes in the prostateArticle · 2021 · 15 citations · Open access · FWCI 1.7789 · Full text ↗
KRAS G>A mutation favors poor tumor differentiation but may not be associated with prognosis in patients with curatively resected duodenal adenocarcinomaArticle · 2012 · 14 citations · Open access · FWCI 0.4744 · Full text ↗
CpG island methylator phenotype and its association with malignancy in sporadic duodenal adenomasArticle · 2014 · 9 citations · Open access · FWCI 0.4097 · Full text ↗
Correction: Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cellsErratum · 2020 · 5 citations · Open access · Full text ↗
Organoids Increase the Predictive Value of in vitro Cancer Chemoprevention Studies for in vivo OutcomeArticle · 2019 · 5 citations · Open access · FWCI 0.5515 · Full text ↗
Improving Sensitivity to Irinotecan Using 5-Azacytidine in Colon Cancer Cell LinesArticle · 2013 · 5 citations · FWCI 0.2988 · Full text ↗
Abstract 4097: Integrative analysis of epigenetic and transcriptional alterations in head and neck squamous cell carcinomasConference Abstract · 2012 · 5 citations · Full text ↗
Correction: Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cellsErratum · 2020 · 1 citations · Open access · Full text ↗
Abstract 1114: Combining anti-androgen therapy and PARP inhibition results in synergistic cytotoxicity of metastatic castration-resistant prostate cancer (mCRPC) cellsConference Abstract · 2017 · 1 citations · Full text ↗
Abstract 1897: Targeting RB-deficient small cell lung cancer with selective CDK2 inhibition by AZD8421.Conference Abstract · 2026 · 0 citations · Full text ↗
Data from Activated ALK Cooperates with N-Myc via Wnt/β-Catenin Signaling to Induce Neuroendocrine Prostate CancerOther · 2023 · 0 citations · Open access · Full text ↗